
$1.165
-0.053 (-4.51%)收盘时
- 最高
- 1.240
- 开盘
- 1.200
- 成交量加权均价
- 1.18
- 成交量
- 114.44K
- 市值
- 18.51M
- 最低
- 1.130
- 成交额
- 134.84K
- 企业价值/息税折旧摊销前利润(TTM)
- 0.00
DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services.
AI 分析 of Scienture Holdings Inc (MEDS)
卖出TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.
估值指标
事件时间线
资讯
7.511-09NewsfilterDataMeds AI Completes First Sale of Peptide Drugs
8.511-02NewsfilterCorexa Pharmacy Approved to Dispense Compounded Peptides
7.510-16NewsfilterCorexa Health Positions for Compounded Peptide Market Growth
7.507-29NewsfilterDatavault AI Expands Data Monetization Technologies with DataMeds AI
2.005-20NewsfilterFormation of DelivMeds AI with Approximate Asset Value of $4 Billion
MEDS 常见问题 —— 由 Alphio AI 解答
DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).
TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.
社区
更多 ↗
相关文章
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。